RenovoRx (NASDAQ:RNXT) Announces Quarterly Earnings Results, Hits Expectations

RenovoRx (NASDAQ:RNXT) issued its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08), FiscalAI reports. The firm had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.42 million. RenovoRx had a negative return on equity of 105.11% and a negative net margin of 994.48%.During the same period in the prior year, the firm posted ($0.40) earnings per share.

Here are the key takeaways from RenovoRx’s conference call:

• RenovoRx achieved initial commercial traction with $1.1M in 2025 revenue, reported Q4 revenue of $238k, has 12 active U.S. centers (33-center near?term pipeline) and is targeting ~36 active sites by year?end 2026 with company guidance that 2026 revenue should be roughly $3M–$4M.
• The company strengthened its balance sheet with an oversubscribed private placement closing on March 23, 2026 that raised ~$10M gross, supplementing ~$7M cash at year?end 2025 to fund commercial scale?up and TIGeR?PaC completion.
• The Phase III TIGeR?PaC trial is nearing its enrollment target (104 of 114 randomized as of March 24, 2026) with 72 of 86 events observed and final data expected in 2027, representing a material clinical catalyst if positive.
• Near?term revenue remains lumpy and scale?constrained (quarterly results swing based on a small number of active centers and timing of first patient treatments), while R&D and SG&A run rates and the need to convert trial sites to commercial use pose execution and dilution risks if commercial adoption is slower than planned.

RenovoRx Stock Down 5.6%

NASDAQ:RNXT opened at $1.01 on Wednesday. The stock’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $1.00. The firm has a market capitalization of $37.02 million, a price-to-earnings ratio of -3.16 and a beta of 1.34. RenovoRx has a 12-month low of $0.70 and a 12-month high of $1.45.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd raised its stake in RenovoRx by 58.6% in the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock valued at $42,000 after acquiring an additional 18,525 shares during the period. Northwestern Mutual Wealth Management Co. bought a new position in RenovoRx during the second quarter worth $98,000. Citadel Advisors LLC acquired a new position in shares of RenovoRx in the third quarter valued at $154,000. Wealthspire Advisors LLC bought a new position in shares of RenovoRx in the fourth quarter valued at about $212,000. Finally, Geode Capital Management LLC raised its position in shares of RenovoRx by 9.9% in the second quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock valued at $467,000 after purchasing an additional 31,730 shares during the period. 3.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on RNXT shares. Wall Street Zen upgraded RenovoRx from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Ascendiant Capital Markets raised their target price on shares of RenovoRx from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of RenovoRx in a report on Monday, December 29th. Finally, JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.